Atea Pharmaceuticals, Inc. Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026. Topline Results from North American Phase 3 C-BEYOND ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...

People coinfected with HIV and hepatitis C virus remain at risk for hepatocellular carcinoma within 6 years of starting ...

A new rapid test for hepatitis C could help identify many more patients who could be cured of the deadly disease, but its use ...

Researchers at the University of Washington have developed a rapid test that quickly detects hepatitis C, but insurance ...

AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...

Research at Elara Capital, said the recent volatility in Maruti Suzuki shares appears to be driven more by profit booking ...

In December 2025, Ashok Leyland's domestic sales surged by 26%, totaling 19,855 units. This growth is attributed to increased ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

Housing Works, a housing organization dedicated to fostering stability and affordability in Central Oregon, has announced ...

Northwestern scientists have created the fastest-ever hepatitis C diagnostic, delivering accurate results in only 15 minutes. The test uses the DASH rapid PCR system, originally developed for COVID, ...